Intact semaglutide in urine accounted for 3.1% of the administered dose in humans and less than 1% in rats
Missing doses or inconsistent timing reduces the compound's efficacy
Li Y, Zhao P, Jiang B, Liu K, Zhang L, Wang H, et al
Hepatology .2026;[Epub] CrossRef Updates on paediatric MASLD: insights from an endocrine lens Natalie Segev, Marialena Mouzaki Diabetologia .2026;[Epub] CrossRef An Integrated NanozymeExosome Platform for MultiTargeted Therapy of MetabolicAssociated Steatotic Liver Disease Kun Yu, Xinwei Li, Yingying Liu, Haonan Zhang, Guojie Liu, Tuo Ji, Yuzhi Gao, Lin Wang, Yuwei Bian, Guohua Chen, Zhiwen Zhao, Feng Wang, Xiaoming Yu, Jiachen He, Xuzhu Gao Advanced Healthcare Materials .2026;[Epub] CrossRef Safety and efficacy of pharmacological interventions for hepatic outcomes of metabolic dysfunction-associated steatotic liver disease: protocol for systematic review and network meta-analysis Kiavash Semnani, Farbod Semnani, Seyed Sahab Aarabi, Shirin Esmaeili, Ehsaneh Taheri, Armita Mahdavi-Gorabi, Mohsen Rajabnia, Shirin Djalalinia, Saba Goodarzi, Amir Kasaeian, Mohammad Shadab Siddiqui, Mostafa Qorbani BMJ Open .2026
Note that this is an entirely voluntary decision
"The results are consistent with prior trials, confirming tirzepatides advantage over semaglutides single GLP-1 action," Londono, who is based in New York City, told Fox News Digital
